|
|
|
|
|
The MegaLigandTM technologyThe MegaLigandTM technology couples the receptor-binding domain of members of the human TNF family with a protein backbone from another human protein to produce a hybrid fusion protein molecule optimised for interaction with the appropriate surface receptor. Typically, only the extracellular domain of the TNF family member is included in the product, and this domain directs the specificity of the resulting MegaLigand product in terms of the cell surface receptor target. The protein backbone is typically a dimer from another unmodified human protein; examples include the collagen binding domain of adiponectin or the Fc domain of an immunoglobulin. Coupling naturally trimerising extracellular domains from TNF family members to a dimer produces a multimeric MegaLigand product that is designed to optimally activate the corresponding cell surface receptor. For example, the natural trimeric form of FasL is inactive, and is only rendered active by ligand clustering at the cell surface. The MegaLigand product mimicks this situation.
Useful links :
Pipeline
- APO010
|
|
|
About Us
Cancer